Hialy Gutierrez, MPH,1,2 Ashwini Shewade, MS, MSc,1 Minghan Dai, MPH,1 Pedro Mendoza-Arana, MD, MSc,3 Octavio Go´mez-Dante´s, MD, MPH,4 Nishant Jain, PhD,5 Irma Khonelidze, MPA,6 Juliet Nabyonga-Orem, MD, MSc,7 Karima Saleh, PhD,8 Yot Teerawattananon, MD, PhD,9 Sania Nishtar, SI, PhD,10 and John Hor

In response to a lack of cost-effective data on screening and early treatment of diabetes and hypertension in resource-limited settings, a model-based economic evaluation was performed on the World Health Organization (WHO)’s Package of Essential Non-communicable (PEN) disease interventions for prim

Objective: To analyze the cost-utility of two common clinical practices for stage IB cervical cancer patients from provider and societal viewpoints. Methods: A decision tree model was conducted to examine value for expenditure between the following: (1) radical hysterectomy with pelvic lymph node

Yot Teerawattananon,1 Sripen Tantivess,1 Pitsaphun Werayingyong,1 Pritaporn Kingkaew,1 Nilar Tin,2 San San Aye,3 Phone Myint3 Abstract Introduction: In 2010, with financial support from the Global Alliance for Vaccine and Immunization’s Health System Strengthening programme, the Government of

Benjarin Santatiwongchai1, Varit Chantarastapornchit1*, Thomas Wilkinson2, Kittiphong Thiboonboon1, Waranya Rattanavipapong1, Damian G Walker3, Kalipso Chalkidou2, Yot Teerawattananon1 1 Health Intervention and Technology Assessment Program, Nonthaburi, Thailand, 2 NICE International,National Insti

Manuel Alexander Haasis1*, Joyce Anne Ceria1, Wantanee Kulpeng2, Yot Teerawattananon2, Marissa Alejandria3 1 National Center for Pharmaceutical Access and Management (NCPAM), Department of Health, Manila, Philippines, 2 Health Intervention and Technology Assessment Program (HITAP), Department of

YOT TEERAWATTANANONa, PRITAPORN KINGKAEWa, TANUNYA KOOPITAKKAJORNa,SITAPORN YOUNGKONGa,b,*, NATTHA TRITASAVITc, PATSRI SRISUWANd and SRIPEN TANTIVESSa aHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand bDepartment of Pharmacy, Faculty of Pharmacy, Mahidol Universi

CATHERINE PITTa,* ANNA VASSALLa, YOT TEERAWATTANANONb, ULLA K. GRIFFITHSa, LORNA GUINNESSa, AMIAN WALKERc, NICOLA FOSTERd and KARA HANSONa a Department of Global Health & Development, London School of Hygiene & Tropical Medicine, London, UK b Health Intervention and Technology Assess

Yot Teerawattananon programme leader1, Alia Luz project associate2, Churnrurtai Kanchanachitra director, Mahidol University Global Health 3, Sripen Tantivess senior researcher 1, On behalf of the Prince Mahidol Award Conference secretariat 1Health Intervention and Technology Assessment Program (

Kalipso Chalkidou , Amanda Glassman , Robert Marten , Jeanette Vega , Yot Teerawattananon , Nattha Tritasavit , Martha Gyansa-Lutterodt , Andreas Seiter Marie Paule Kieny , Karen Hofmani , Anthony J Culyerj Abstract Governments in low- and middle-income countries are legitimizing the imp